| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b53290ef881bc16e92cfbaf0cd9605a7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2230-0054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2210-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-91 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate |
2004-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d64fd04a5cdcc9c66410d32896af5faf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65df49f46a12aa4f4ba266ed26e3a994
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9fdcf1269824f6e4c051ca7ec6343b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea8a6a8e6262888d42d8a96720b849b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d6d58a27f731e22f7d28f18ae71baba |
| publicationDate |
2012-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2433661-A1 |
| titleOfInvention |
Anti-restenotic agents to be delivered from a stent |
| abstract |
The invention discloses an anti-restenotic drug to be delivered from a stent loaded with a predetermined amount of the anti-restenotic drug for use in a method of reducing restenosis, the method comprising implanting the stent having no more than the predetermined amount of the anti-restenotic drug; and delivering the anti-restenotic drug from a bioresorbable polymer matrix reservoir in the stent, wherein the polymer matrix is completely resorbed between 30 days and 90 days, inclusive, and the entire predetermined amount elutes from the stent before the polymer matrix is resorbed. |
| priorityDate |
2003-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |